{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:37:45Z","timestamp":1787002665580,"version":"build-2736575974"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T00:00:00Z","timestamp":1566345600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Bone Marrow Transplant"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41409-019-0640-z","type":"journal-article","created":{"date-parts":[[2019,8,21]],"date-time":"2019-08-21T11:03:08Z","timestamp":1566385388000},"page":"117-125","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["Allogeneic stem cell transplantation improves survival in relapsed Hodgkin lymphoma patients achieving complete remission after salvage treatment"],"prefix":"10.1038","volume":"55","author":[{"name":"on behalf of GATMO (Grupo Argentino de Trasplante de M\u00e9dula \u00d3sea)","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Marta","family":"Rivas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariano","family":"Berro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda Virginia","family":"Prates","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebasti\u00e1n","family":"Yantorno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorena","family":"Fiad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Alberto","family":"Arbelbide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9892-5543","authenticated-orcid":false,"given":"Ana Lisa","family":"Basquiera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo Ariel","family":"Ferini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan Jos\u00e9","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pablo Andr\u00e9s","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leandro","family":"Riera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Jarchum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Baso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Real","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mart\u00edn","family":"Castro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregorio","family":"Jaimovich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juliana","family":"Martinez Rol\u00f3n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cecilia","family":"Foncuberta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Kusminsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,21]]},"reference":[{"key":"640_CR1","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1002\/ajh.23750","volume":"89","author":"SM Ansell","year":"2014","unstructured":"Ansell SM. Hodgkin lymphoma: 2014 update on diagnosis, risk-stratification, and management. Am J Hematol. 2014;89:771\u20139.","journal-title":"Am J Hematol"},{"key":"640_CR2","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1016\/0140-6736(93)92411-L","volume":"341","author":"DC Linch","year":"1993","unstructured":"Linch DC, Winfield D, Goldstone AH, Moir D, Hancock B, McMillan A, et al. Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin\u2019s disease: results of a BNLI randomized trial. Lancet. 1993;341:1051\u20134.","journal-title":"Lancet"},{"issue":"10","key":"640_CR3","doi-asserted-by":"publisher","first-page":"1525","DOI":"10.1038\/s41409-019-0516-2","volume":"54","author":"Rafael F. Duarte","year":"2019","unstructured":"Duarte RF, Labopin M, Bader P et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019. Bone Marrow Transplant. 2019. \nhttps:\/\/doi.org\/10.1038\/s41409-019-0516-2\n\n.","journal-title":"Bone Marrow Transplantation"},{"issue":"Nov","key":"640_CR4","doi-asserted-by":"crossref","first-page":"1812","DOI":"10.1056\/NEJMoa1002965","volume":"363","author":"A Younes","year":"2010","unstructured":"Younes A, Bartlett NL, Leonard JP, Kennedy DA, Lynch CM, Sievers EL, et al. Brentuximab vedotin (SGN-35) for relapsed CD30-positive lymphomas. N Engl J Med. 2010;363(Nov):1812\u201321.","journal-title":"N Engl J Med"},{"key":"640_CR5","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","volume":"17","author":"A Younes","year":"2016","unstructured":"Younes A, Santoro A, Engert A, Zinzani PL, Timmerman JM, Ansell S, et al. Nivolumab for classical Hodgkin\u2019s lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial. Lancet Oncol. 2016;17:1283\u201394.","journal-title":"Lancet Oncol"},{"key":"640_CR6","doi-asserted-by":"crossref","first-page":"3733","DOI":"10.1200\/JCO.2016.67.3467","volume":"34","author":"P Armand","year":"2016","unstructured":"Armand P, Shipp MA, Moskowitz CH, Michot JM, ZinzaniPL, Kuruvilla J, et al. Programmed death-1 blockade with pembrolizumab in patients with classical hodgkin lymphoma after brentuximab vedotin failure. J Clin Oncol. 2016;34:3733\u20139.","journal-title":"J Clin Oncol"},{"key":"640_CR7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1111\/bjh.12582","volume":"164","author":"GP Collins","year":"2014","unstructured":"Collins GP, Pocock C, Peggs KS, Kayani I, Sureda A, Illidge T, et al. Guideline on the management of primary resistant and relapsed classical Hodgkin lymphoma. Br J Haematol. 2014;164:39\u201352.","journal-title":"Br J Haematol"},{"key":"640_CR8","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1182\/bloodadvances.2017011130","volume":"10","author":"CH Moskowitz","year":"2018","unstructured":"Moskowitz CH. Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily. Blood Adv. 2018;10:821\u20134.","journal-title":"Blood Adv"},{"key":"640_CR9","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1182\/bloodadvances.2017011122","volume":"2","author":"KS Peggs","year":"2018","unstructured":"Peggs KS. Should all patients with Hodgkin lymphoma who relapse after autologous SCT be considered for allogeneic SCT? Blood Adv. 2018;2:817\u201320.","journal-title":"Blood Adv"},{"key":"640_CR10","doi-asserted-by":"crossref","first-page":"310","DOI":"10.3324\/haematol.2011.045757","volume":"97","author":"A Sureda","year":"2012","unstructured":"Sureda A, Canals C, Arranz R, Caballero D, Ribera JM, Brune M, et al. Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin\u2019s lymphoma. Results of the HDR-ALLO study\u2014a prospective clinical trial by the Grupo Espa\u00f1ol de Linfomas\/ Trasplante de M\u00e9dula Osea (GEL\/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Haematologica. 2012;97:310\u20137.","journal-title":"Haematologica"},{"key":"640_CR11","doi-asserted-by":"crossref","first-page":"4314","DOI":"10.1200\/JCO.2001.19.23.4314","volume":"19","author":"G Akpek","year":"2001","unstructured":"Akpek G, Ambinder RF, Piantadosi S, Abrams RA, Brodsky RA, Vogelsang GB, et al. Long-term results of blood and marrow transplantation for Hodgkin\u2019s lymphoma. J Clin Oncol. 2001;19:4314\u201321.","journal-title":"J Clin Oncol"},{"key":"640_CR12","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1016\/S0140-6736(05)66659-7","volume":"365","author":"KS Peggs","year":"2005","unstructured":"Peggs KS, Hunter A, Chopra R, Parker A, Mahendra P, Milligan D, et al. Clinical evidence of a graft-versus-Hodgkin\u2019s- lymphoma effect after reduced-intensity allogeneic transplantation. Lancet. 2005;365:1934\u201341.","journal-title":"Lancet"},{"key":"640_CR13","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.bbmt.2008.08.014","volume":"14","author":"LM Burroughs","year":"2008","unstructured":"Burroughs LM, O\u2019Donnell PV, Sandmaier BM, Storer BE, Luznik L, Symons HJ, et al. Comparison of outcomes of HLA-matched related, unrelated, or HLA-haploidentical related hematopoietic cell transplantation following nonmyeloablative conditioning for relapsed or refractory Hodgkin lymphoma. Biol Blood Marrow Transpl. 2008;14:1279\u201387.","journal-title":"Biol Blood Marrow Transpl"},{"key":"640_CR14","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1200\/JCO.2010.32.1711","volume":"29","author":"KS Peggs","year":"2011","unstructured":"Peggs KS, Kayani I, Edwards N, Kottaridis P, Goldstone AH, Linch DC, et al. Donor lymphocyte infusions modulate relapse risk in mixed chimeras and induce durable salvage in relapsed patients after T-cell-depleted allogeneic transplantation for Hodgkin\u2019s lymphoma. J Clin Oncol. 2011;29:971\u20138.","journal-title":"J Clin Oncol"},{"key":"640_CR15","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1200\/JCO.2010.33.2437","volume":"29","author":"PJ Greaves","year":"2011","unstructured":"Greaves PJ, Gribben JG. Demonstration of durable graft versus lymphoma effects in Hodgkin\u2019s lymphoma. J Clin Oncol. 2011;29:952.","journal-title":"J Clin Oncol"},{"key":"640_CR16","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.bbmt.2012.08.014","volume":"19","author":"A Raiola","year":"2013","unstructured":"Raiola A, Dominietto A, Ghiso A, Di Grazia C, Lamparelli T, Gualandi F, et al. Unmanipulated haploidentical bone marrow transplantation and posttransplantion cyclophosphamide for hematologic malignancies after myeloablative conditioning. Biol Blood Marrow Transplant. 2013;19:117\u201322.","journal-title":"Biol Blood Marrow Transplant"},{"key":"640_CR17","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/bmt.2013.166","volume":"49","author":"A Raiola","year":"2014","unstructured":"Raiola A, Dominietto A, Bramanti S, Ghiso A, Galaverna F, Bramanti S, et al. Unmanipulated haploidentical BMT following non-myeloablative conditioning and post-transplantation CY for advanced Hodgkin\u2019s lymphoma. Bone Marrow Transpl. 2014;49:190\u20134.","journal-title":"Bone Marrow Transpl"},{"key":"640_CR18","doi-asserted-by":"crossref","first-page":"296","DOI":"10.3109\/10428194.2013.802780","volume":"55","author":"M Messer","year":"2014","unstructured":"Messer M, Steinzen A, Verv\u00f6lgyi E, Lerch C, Richter B, Dreger P, et al. Unrelated and alternative donor allogeneic stem cell transplant in patients with relapsed or refractory Hodgkin lymphoma: a systematic review. Leuk Lymphoma. 2014;55:296\u2013306.","journal-title":"Leuk Lymphoma"},{"key":"640_CR19","doi-asserted-by":"crossref","first-page":"3456","DOI":"10.1182\/blood.V98.12.3456","volume":"98","author":"L Luznik","year":"2001","unstructured":"Luznik L, Jalla S, Engstrom LW, Iannone R, Fuchs EJ, et al. Durable engraftment of major histocompatibility complex-incompatible cells after nonmyeloablative conditioning with fludarabine, low-dose total body irradiation, and posttransplantation cyclophosphamide. Blood. 2001;98:3456\u201364.","journal-title":"Blood"},{"key":"640_CR20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1016\/j.bbmt.2017.01.079","volume":"23","author":"M Pitombeira de Lacerda","year":"2017","unstructured":"Pitombeira de Lacerda M, Arrais Rodrigues C, Pereira AD, Novis Y, Fonseca M, Rocha V, et al. Hla-Haploidentical transplantation for relapsed\/refractory hodgkin lymphoma: a multicenter analysis. Biol Blood Marrow Transpl. 2017;23:705\u201370.","journal-title":"Biol Blood Marrow Transpl"},{"key":"640_CR21","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1200\/JCO.1996.14.2.572","volume":"14","author":"JL Gajewski","year":"1996","unstructured":"Gajewski JL, Phillips GL, Sobocinski KA, Armitage JO, Gale RP, Champlin RE, et al. Bone marrow transplants from HLA-identical siblings in advanced Hodgkin\u2019s disease. J Clin Oncol. 1996;14:572\u20138.","journal-title":"J Clin Oncol"},{"key":"640_CR22","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1200\/JCO.1996.14.4.1291","volume":"14","author":"N Milpied","year":"1996","unstructured":"Milpied N, Fielding AK, Pearce RM, Ernst P, Goldstone AH. Allogeneic bone marrow transplant is not better than autologous transplant for patient with relapsed Hodgkin\u2019s disease. European Group for Blood and Bone Marrow Transplantation. J Clin Oncol. 1996;14:1291\u20136.","journal-title":"J Clin Oncol"},{"key":"640_CR23","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1200\/JCO.2007.13.2415","volume":"26","author":"A Sureda","year":"2008","unstructured":"Sureda A, Robinson S, Canals C, Carella AM, Boogaerts MA, Caballero D, et al. Reduced-intensity conditioning compared with conventional allogeneic stem-cell transplantation in relapsed or refractory Hodgkin lymphoma: an analysis from the lymphoma working party of the European Group for Blood and Marrow Transplantation. J Clin Oncol. 2008;26:455\u201362.","journal-title":"J Clin Oncol"},{"key":"640_CR24","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1093\/annonc\/mdw421","volume":"27","author":"S Genadieva-Stavrik","year":"2016","unstructured":"Genadieva-Stavrik S, Boumendil A, Dreger P, Peggs K, Briones J, Corradini P, et al. Myeloablative versus reduced intensity allogeneic stem cell transplantation for relapsed\/refractory Hodgkin\u2019s lymphoma in recent years: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Ann Oncol. 2016;27:2251\u20137.","journal-title":"Ann Oncol"},{"key":"640_CR25","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, et al. Revised response criteria for malignant lymphoma. J Clin Oncol. 2007;25:579\u201386.","journal-title":"J Clin Oncol"},{"key":"640_CR26","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","volume":"15","author":"A Bacigalupo","year":"2009","unstructured":"Bacigalupo A, Ballen K, Rizzo D, Giralt S, Lazarus H, Ho V, et al. Defining the intensity of conditioning regimens: working definitions. Biol Blood Marrow Transpl. 2009;15:1628\u201333.","journal-title":"Biol Blood Marrow Transpl"},{"key":"640_CR27","doi-asserted-by":"crossref","first-page":"4208","DOI":"10.1182\/blood-2010-09-288373","volume":"117","author":"J Kuruvilla","year":"2011","unstructured":"Kuruvilla J, Keating A, Crump M. How I treat relapsed and refractory Hodgkin lymphoma. Blood. 2011;117:4208\u201317.","journal-title":"Blood"},{"key":"640_CR28","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.hoc.2013.09.001","volume":"28","author":"Mark Hertzberg.","year":"2014","unstructured":"Hertzberg. Mark. Relapsed\/refractory Hodgkin lymphoma what is the best salvage therapy and do we need RIC-AlloSCT? Hematol Oncol Clin N Am. 2014;28:123\u201347.","journal-title":"Hematol Oncol Clin N Am"},{"key":"640_CR29","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1111\/j.1365-2141.2010.08492.x","volume":"152","author":"P Corradini","year":"2011","unstructured":"Corradini P. Allogeneic transplantation for Hodgkin\u2019s lymphoma. Br J Haematol. 2011;152:261\u201372.","journal-title":"Br J Haematol"},{"key":"640_CR30","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.3324\/haematol.2012.072090","volume":"98","author":"E Van Den Neste","year":"2013","unstructured":"Van Den Neste E, Casasnovas O, Andr\u00e9 M, Touati M, Senecal D, Edeline V, et al. Classical Hodgkin\u2019s lymphoma: the Lymphoma Study Association guidelines for relapsed and refractory adult patients eligible for transplant. Haematologica. 2013;98:1185\u201395.","journal-title":"Haematologica"},{"key":"640_CR31","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.bbmt.2015.02.022","volume":"21","author":"MA Perales","year":"2015","unstructured":"Perales MA, Cebeiro I, Carpenter PA, Burns LJ, Chen R, Cole PD, et al. Role of cytotoxic therapy with hematopoietic cell transplantation in the treatment of Hodgkin lymphoma: guidelines from the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transpl. 2015;21:971\u201383.","journal-title":"Biol Blood Marrow Transpl"},{"key":"640_CR32","unstructured":"Hope R, Advani R, et al. NCCN. National Comprehensive Cancer Network clinical guidelines on oncology. Hodgkin lymphoma. (v2.2019). \nhttps:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/hodgkins.pdf\n\n."},{"key":"640_CR33","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","volume":"30","author":"A Younes","year":"2012","unstructured":"Younes A, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Chen R, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma. J Clin Oncol. 2012;30:2183\u20139.","journal-title":"J Clin Oncol"},{"key":"640_CR34","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1002\/hon.2119","volume":"32","author":"S Garciaz","year":"2014","unstructured":"Garciaz S, Coso D, Peyrade F, F\u00fcrst S, Duran S, Chetaille B, et al. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and\/or refractory Hodgkin lymphoma. Hematol Oncol. 2014;32:187\u201391.","journal-title":"Hematol Oncol"},{"key":"640_CR35","first-page":"1","volume":"10","author":"T Illidge","year":"2014","unstructured":"Illidge T, Bouabdallah R, Chen R, Gopal AK, Moskowitz, Ramchandren R, et al. Allegeneic transplant following Brentuximab Vedotin in patients with relapsed or refractory Hodgkin lymphoma and systemic anaplastic Large cell. Leuk Lymphoma. 2014;10:1\u201334.","journal-title":"Leuk Lymphoma"},{"key":"640_CR36","doi-asserted-by":"crossref","first-page":"230","DOI":"10.3324\/haematol.13441","volume":"94","author":"SP Robinson","year":"2009","unstructured":"Robinson SP, Sureda A, Canals C, Russell N, Caballero D, Bacigalupo A, et al. Reduced intensity conditioning allogeneic stem cell transplantation for Hodgkin\u2019s lymphoma: identification of prognostic factors predicting outcome. Haematologica. 2009;94:230\u20138.","journal-title":"Haematologica"},{"key":"640_CR37","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.3324\/haematol.2012.080895","volume":"98","author":"A Marcais","year":"2013","unstructured":"Marcais A, Porcher R, Robin M, Mohty M, Michalet M, Blaise D, et al. Impact of disease status and stem cell source on the results of reduced intensity conditioning transplant for Hodgkin\u2019s lymphoma: a retrospective study from the French Society of Bone Marrow Transplantation and Cellular Therapy (SFGM-TC). Haematologica. 2013;98:1467\u201375.","journal-title":"Haematologica"},{"key":"640_CR38","doi-asserted-by":"crossref","first-page":"257","DOI":"10.3324\/haematol.11828","volume":"93","author":"P Anderlini","year":"2008","unstructured":"Anderlini P, Saliba R, Acholonu S, Giralt SA, Andersson B, Ueno NT, et al. Fludarabine-melphalan as a preparative regimen for reduced-intensity conditioning allogeneic stem cell transplantation in relapsed and refractory Hodgkin\u2019s lymphoma: the updated M.D. Anderson Cancer Center experience. Haematologica. 2008;93:257\u201364.","journal-title":"Haematologica"},{"key":"640_CR39","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1182\/blood-2016-02-699850","volume":"128","author":"R Chen","year":"2016","unstructured":"Chen R, Gopal A, Younes A, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562\u20136.","journal-title":"Blood"},{"key":"640_CR40","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.bbmt.2014.06.037","volume":"20","author":"R Chen","year":"2014","unstructured":"Chen R, Palmer JM, Tsai NC, Thomas S, Paris T, Popplewell L, et al. Brentuximab vedotin is associated with improved progression-free survival after allogeneic transplantation for Hodgkin lymphoma. Biol Blood Marrow Transpl. 2014;20:1864\u20138.","journal-title":"Biol Blood Marrow Transpl"},{"key":"640_CR41","doi-asserted-by":"crossref","first-page":"2471","DOI":"10.1182\/blood-2016-11-749556","volume":"129","author":"C Herbaux","year":"2017","unstructured":"Herbaux C, Gauthier J, Brice P, Drumez E, Ysebaert L, Doyen H, et al. Efficacy and tolerability of nivolumab after allogeneic transplantation for relapsed Hodgkin lymphoma. Blood. 2017;129:2471\u20138.","journal-title":"Blood"},{"issue":"Jan","key":"640_CR42","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.bbmt.2018.08.028","volume":"25","author":"A Ijaz","year":"2019","unstructured":"Ijaz A, Khan A, Malik S, et al. Significant risk of graft-versus-host disease with exposure to checkpoint inhibitors before and after allogeneic transplantation. Biol Blood Marrow Transpl. 2019;25(Jan):94\u20139.","journal-title":"Biol Blood Marrow Transpl"},{"key":"640_CR43","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1016\/j.bbmt.2017.11.030","volume":"24","author":"J Marrioti","year":"2018","unstructured":"Marrioti J, Devillier R, Bramanti S, et al. T cell-replete haploidentical transplantation with post-transplantation cyclophosphamide for Hodgkin lymphoma relapsed after autologous transplantation: reduced incidence of relapse and of chronic graft-versus-host disease compared with HLA-identical related donors. Biol Blood Marrow Transpl. 2018;24:627\u201332.","journal-title":"Biol Blood Marrow Transpl"},{"key":"640_CR44","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/s41409-017-0018-z","volume":"53","author":"J Gauthier","year":"2018","unstructured":"Gauthier J, Poir\u00e9 X, Gac AC, et al. Better outcome with haploidentical over HLA-matched related donors in patients with Hodgkin\u2019s lymphoma undergoing allogeneic haematopoietic cell transplantation-a study by the Francophone Society of Bone Marrow Transplantation and Cellular Therapy. Bone Marrow Transpl. 2018;53:400\u20139.","journal-title":"Bone Marrow Transpl"},{"issue":"30","key":"640_CR45","doi-asserted-by":"crossref","first-page":"3425","DOI":"10.1200\/JCO.2017.72.6869","volume":"35","author":"Carmen Mart\u00ednez","year":"2017","unstructured":"Martinez C, Gayoso J, Canals C. et al. Post-transplantation cyclophosphamide-based haploidentical transplantation as alternative to matched sibling or unrelated donor transplantation for Hodgkin lymphoma: a registry study of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation. J Clin Oncol. 2017;35:3425\u201332.","journal-title":"Journal of Clinical Oncology"},{"key":"640_CR46","doi-asserted-by":"publisher","unstructured":"Ahmed S, Kanakry J, Ahn K, et al. Lower GVHD and relapse risk in PTCy-based haploidentical vs matched sibling donor RIC transplant for Hodgkin lymphoma. Biology of Blood and Marrow Transplantation. 2019. \nhttps:\/\/doi.org\/10.1016\/j.bbmt\n\n. 2019. 05.025.","DOI":"10.1016\/j.bbmt"}],"container-title":["Bone Marrow Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0640-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0640-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41409-019-0640-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T17:15:20Z","timestamp":1684602920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41409-019-0640-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,21]]},"references-count":46,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["640"],"URL":"https:\/\/doi.org\/10.1038\/s41409-019-0640-z","relation":{},"ISSN":["0268-3369","1476-5365"],"issn-type":[{"value":"0268-3369","type":"print"},{"value":"1476-5365","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,21]]},"assertion":[{"value":"7 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 August 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}